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Rakshamani Tripathi 1, Zulong Liu1, Aditi Jain1,7, Anastasia Lyon1, Christina Meeks1, Dana Richards2,
Jinpeng Liu3, Daheng He3, Chi Wang3, Marika Nespi4, Andrey Rymar4, Peng Wang5, Melissa Wilson
Rina Plattner 1 ✉

Metastatic melanoma remains an incurable disease for many patients due to the limited
success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic
burden for patients with melanomas harboring BRAF mutations; however, most eventually
relapse due to acquired resistance. Here, we demonstrate that ABL1/2 kinase activities and/
or expression are potentiated in cell lines and patient samples following resistance, and ABL1/
2 drive BRAF and BRAF/MEK inhibitor resistance by inducing reactivation of MEK/ERK/MYC
signaling. Silencing/inhibiting ABL1/2 blocks pathway reactivation, and resensitizes resistant
cells to BRAF/MEK inhibitors, whereas expression of constitutively active ABL1/2 is sufﬁcient
to promote resistance. Signiﬁcantly, nilotinib (2nd generation ABL1/2 inhibitor) reverses
resistance, in vivo, causing prolonged regression of resistant tumors, and also, prevents
BRAFi/MEKi resistance from developing in the ﬁrst place. These data indicate that repurposing the FDA-approved leukemia drug, nilotinib, may be effective for prolonging survival for
patients harboring BRAF-mutant melanomas.
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elanoma incidences continue to increase, and the disease remains incurable for many due to its metastatic
nature and high rate of therapeutic resistance (Cancer.
Net). Immunotherapy increases the cure rate for some advanced
cases; however, 50–60% of patients do not respond and some
cannot tolerate the therapy1,2. Moreover, for those with high
metastatic burden, immunotherapy may not sufﬁciently reduce
tumor burden or induce remission1,2. Melanomas harboring
activating BRAF-V600E/K mutations (70–88%) can be treated
with BRAF inhibitors (BRAFi; e.g. vemurafenib, dabrafenib)3;
however, some BRAF-mutant melanomas are intrinsically resistant, and many that respond initially, develop resistance during
treatment (median progression-free survival—PFS, 5–7 months)4.
Since a common BRAFi resistance mechanism involves BRAFindependent activation of MEK, combining BRAF and MEK
inhibitors (MEKi; e.g. trametinib, cobimetinib) delays resistance
(median PFS, 12 months)3. However, the vast majority still succumb to the disease due to acquired resistance. Tumors circumvent the effects of BRAFi and BRAFi/MEKi via (1) reactivation of
ERK due to mutations in MAP2K1 (MEK1), MAP2K2 (MEK2)5,
MAP3K8 (COT; TPL-2)6, NRAS or KRAS5, overexpression of
receptor tyrosine kinases (RTKs)5, or expression of BRAF-V600E
splice variants3; (2) overexpression of the master melanocyte
transcription factor, MITF5; or (3) PI3K/AKT activation by
RTKs7 or as a result of PTEN or AKT mutations5,7,8. Thus, new
drug combinations are needed to increase the 5-year survival rate
for patients with advanced disease.
ABL1 (a.k.a. c-Abl) and ABL2 (a.k.a. Arg; Abl-related-Gene)
non-receptor tyrosine kinases are best known for their oncogenic
role in human leukemia, where they are partners in chromosomal
translocations (e.g. BCR-ABL1, ETV6-ABL2) that activate the
kinases and drive disease progression9. The ﬁrst-generation ABL
inhibitor, imatinib, has been used for decades to treat BCR-ABL1driven chronic myelogenous leukemia (CML), and second (e.g.
nilotinib) and third (e.g. ponatinib)-generation drugs were
developed to combat imatinib resistance9. Nilotinib, which is
more efﬁcacious than imatinib, is well-tolerated (most common
adverse effects are mild liver damage, nausea, vomiting, rash, and
musculoskeletal pain)10.
Accumulating evidence supports a role for ABL1/2 in solid
tumors where they are activated downstream of other kinases or
are mutationally activated in a small subset9,11. ABL1 activation
in cytoplasm/plasma membrane compartments has pro-survival/
oncogenic roles, whereas nuclear ABL1 often induces apoptosis9.
In contrast, ABL2, which promotes invasion (and sometimes,
proliferation), is only present in the cytoplasm/plasma
membrane9,12. ABL1/2 are highly active in 40–60% of melanomas, and drive disease progression13–15; however, their role in
therapeutic resistance has not been explored. Here, we utilize
in vitro and in vivo experiments and patient samples to
demonstrate that ABL1/2 drive resistance to BRAFi and BRAFi/
MEKi. Although resistance mechanisms differ among the lines
queried, targeting ABL kinases reverses resistance in all lines
tested, indicating that the kinases are critical signaling nodes.
Indeed, nilotinib, an ABL1/2 inhibitor that has been FDAapproved for more than a decade, reverses and prevents resistance, in vivo. These data have strong clinical relevance as they
indicate that nilotinib may prolong patient survival in both
BRAFi/MEKi-refractory and treatment-naïve settings.
Results
ABL1/2 are activated following BRAFi or BRAFi/MEKi resistance. Since resistance is a major impediment to long-term survival for patients with metastatic melanoma, and ABL kinases are
activated by ERK pathway components (BRAF, ERK) and activate
2

ERK16, we tested whether ABL1/2 drive BRAFi or BRAFi/MEKi
resistance. All cell lines utilized in subsequent experiments harbor
BRAF-V600E mutations. Clonal, BRAFi-resistant (-BR) lines
derived from Mel1617 and 451-Lu were developed by Herlyn and
colleagues17 (Mel1617-BR, 451-Lu-BR). We established polyclonal BRAFi-resistant M14 (M14-BR) and BRAFi/MEKi-resistant (M14-BMR, Mel1617-BMR) lines (see “Methods”), since this
more accurately mimics resistance, in vivo. All new resistant lines
demonstrate high level resistance to PLX4720 (PLX; BRAFi; -BR)
or dabrafenib/trametinib (D/T; BRAFi/MEKi; -BMR) (Supplementary Fig. 1a–c). Importantly, ABL1 and/or ABL2 kinase
activities are elevated in resistant lines (compared to parental
cells; Fig. 1a and Supplementary Fig. 1d). Kinase activities were
assessed using highly sensitive and speciﬁc in vitro kinase assays,
which involve incubating ABL1 or ABL2 immunoprecipitates
with their substrate, GST-CRK, and gamma-32P-labeledATP18,19. Consistent with the notion that cytoplasmic retention
induces ABL1’s transforming function9, ABL1 cytoplasmic localization (cytoplasmic:nuclear ratio) also is increased in resistant
cells (Fig. 1b and Supplementary Fig. 1e). Cytoplasmic retention
of ABL1 is mediated by interaction with 14-3-3 proteins, which
sequester ABL1 in the cytoplasm by binding a phosphorylated
threonine residue (ABL1-T735)20,21. BRAFi/MEKi-resistant lines
have increased T735 phosphorylation (Fig. 1c), consistent with
fractionation data demonstrating increased ABL1 cytoplasmic
retention. Increased ABL1 mRNA in primary melanomas correlates with activated ABL1 signaling and disease progression14,15.
Importantly, ABL1 mRNA levels also are signiﬁcantly elevated in
patient samples following relapse on BRAFi or BRAFi/MEKi
compared to matched samples obtained prior to treatment (using
four RNAseq or microarray databases; Fig. 1d and Supplementary
Fig. 1f). Taken together, these data demonstrate that ABL1/2
expression and/or activities are potentiated following BRAFi or
BRAFi/MEKi resistance.
To identify the mechanism by which ABL1/2 are activated
following resistance, we assessed the activity of SRC family
kinases (SFKs), which phosphorylate and activate ABL1/216,22,23.
SFK activity (pY416) is elevated in many resistant lines, and
inhibition of SFK activity using SFK inhibitor, SU6656, prevents
ABL1 and ABL2 activation (kinase assays) in M14-resistant lines
(Fig. 1e), indicating that SRC activation contributes to ABL1/2
activation during resistance in these cells. Consistent with the
kinase assay data, phosphorylation of CRKL (ABL1/2 substrate)
on ABL1/2 phosphorylation sites, a well-accepted read-out of
ABL1/2 activities13,24, also is inhibited by SU6656 treatment
(Fig. 1e). We used the lowest dose of SU6656 that efﬁciently
reduces SFK activity in melanoma cells (10 μM), and we
previously showed that this dose has no direct effect on ABL1
or ABL2 as it does not reduce their activities in cells that lack SFK
expression25. Interestingly, SU6656 has little effect on ABL1/2
activities in Mel1617-BR; reduces ABL1 but not ABL2 activity in
Mel1617-BMR; and reduces ABL2 but not ABL1 activity in 451Lu-BR (Supplementary Fig. 1g). Thus, although SFKs contribute
to ABL1/2 activation in M14-resistant lines, additional kinases
also are involved in activating ABL1/2 in Mel1617 and 451-Lu
resistant lines.
Targeting ABL1/2 reverses BRAFi and BRAFi/MEKi resistance. Next, we tested whether ABL1/2 activation is required for
resistance. Parental and BRAFi-resistant lines (-BR) were treated
with vehicle, nilotinib, PLX4720 (PLX; BRAFi), or the combination. As expected, parental cells are highly sensitive to PLX alone
(cell viability, colony-forming assays), whereas resistant cells are
impervious to the effects of the drug (Fig. 2a–e and Supplementary Fig. 2a, b). Treatment with nilotinib alone has little effect
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Fig. 1 ABL kinase activities are potentiated following resistance to BRAF and BRAF/MEK inhibitors. a Parental (M14, Mel1617, 451-Lu), BRAFi (-BR), or
BRAFi/MEKi-resistant (-BMR) cell lines were serum-starved and subjected to in vitro kinase assay (top two panels) or western blot (rest of the panels) for
total protein expression. For kinase assays, ABL1 was immunoprecipitated with K12 antibody, whereas ABL2 was immunoprecipitated with ABL2-speciﬁc
antibody19,62, and IPs incubated with substrate (GST-CRK) and radiolabeled (gamma-32P)-ATP (see “Methods”). Kinase quantitation for n = 3–5 biological
replicates is shown in Supplementary Fig. 1d. b Resistant cell lines (a) were fractionated into nuclear (nuc) and cytoplasmic (cyto) fractions, equal
percentages of cytoplasmic/nuclear fractions loaded for each line, and fractions blotted with the indicated antibodies. Lamin and tubulin blots were used to
demonstrate the purity of nuclear and cytoplasmic fractions, respectively. ABL1 cytoplasmic:nuclear ratio is noted for each cell line, and quantitation for all
lines is shown in Supplementary Fig. 1e. A representative of n = 2 independent experiments is shown. c Lysates from a were blotted with the indicated
antibodies and quantiﬁed. Graph shown is mean ± SEM for three independent experiments. **p = 0.006 using single sample t-tests (two-sided) and Holm’s
adjustment for multiple comparisons. d Primary human paired melanoma datasets (RNAseq-77940, 50535, 65185, EGAS00001000992; microarray50509) were analyzed for ABL1 mRNA levels pre-/post-BRAFi, MEKi, or BRAFi/MEKi treatment. Numbers in each column indicate number of cases. All
cases were included; repeated analyses using particular cut-off values are shown in Supplementary Fig. 1f). p = 0.008 for the combined set using a twosided binomial (right). e Parental and resistant cells were serum-starved, treated with vehicle (DMSO) or SFK inhibitor, SU6656 (10 μM), for 16 h and
lysates were subjected to in vitro kinase assay (top two panels) and western blot (all other panels) as in a.

on survival and colony formation in parental or resistant Mel1617
and M14 lines; however, nilotinib modestly reverses intrinsic
resistance (parental lines; viability assays) and reverses acquired
resistance (resistant lines) when combined with PLX (Fig. 2a–d
and Supplementary Fig. 2a, b). Unlike Mel1617-BR and M14-BR,
nilotinib alone efﬁciently reduces the viability and colony formation of 451-Lu-BR, whereas the effects are more modest in the
parental line (Fig. 2e, f). Addition of PLX reduces the anti-proliferative/survival effects of nilotinib, although the effects remain
greater than PLX alone. Importantly, nilotinib alone (451-Lu-BR)
and nilotinib+PLX (Mel1617-BR, M14-BR) induce PARP and
caspase-3 cleavage (Fig. 2g), and inhibit colony formation following drug removal (Fig. 2b, d, f), indicating that the effects are

permanent. Similar results are observed with ponatinib, a thirdgeneration ABL1/2 inhibitor with a different set of non-ABL
targets as well as with GNF-5, a highly speciﬁc, but less potent
allosteric ABL1/2 inhibitor with no other known targets (Supplementary Fig. 2c–f)12. Moreover, expression of nilotinibresistant forms of ABL1/2 (T315I) rescues nilotinib-mediated
inhibition of viability in the presence of PLX, indicating that
nilotinib’s effects are mediated predominantly by ABL1/2 (Supplementary Fig. 2g). Consistent with these data, expression of
constitutively active forms of ABL1/2 (P242E/P249E; PP)23,26
into melanoma cells lacking highly active ABL1/2 and harboring
BRAF-V600E (WM164; gain-of-function experiment)16 is sufﬁcient to induce BRAFi resistance (Fig. 2h and Supplementary
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Fig. 2 ABL1/2 inhibition reverses resistance to BRAF inhibitors. a, c, e Viability (CellTiter Glo) assays for cells treated with vehicle (veh) or nilotinib (nilo)
alone (e (right)) in the absence/presence of BRAFi, PLX4720 (doses shown) for 72 h (a, c, e (left)). Nilotinib doses: a 5 or 6 μM; c, e 5 μM. Results are
mean ± SEM for three independent experiments performed in triplicate. Additional drug doses are shown in Supplementary Fig. 2a, b. *p < 0.05, **p ≤ 0.01,
***p < 0.001 using two-sample t-tests (two sided). Actual p values (left→right): a 0.0029, 0.00016; c 0.039, 0.0068; e (left) 0.016, 0.043, 0.015; e (right)
0.019, 0.035, 0.035. b, d, f Colony assays. Cells were treated with nilotinib (b 4 μM, d 3 μM; f doses shown) and/or PLX4720 (2.5 μM) for 7 days, wells
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Fig. 2h). Thus, ABL kinases drive acquired BRAFi resistance, and
ABL1/2 inhibitors cooperate with BRAFi to prevent viability in
some lines (M14-BR, Mel1617-BR) or are highly effective on their
own for others (451-Lu-BR).
Metastatic melanoma is currently treated with BRAFi/MEKi
since it increases PFS over BRAFi alone4. Thus, we examined
whether ABL1/2 also drive resistance to BRAFi/MEKi. Importantly, targeting ABL1/2 (nilotinib, ponatinib, GNF-5, ABL1/2
shRNA) in BRAFi/MEKi-resistant lines (M14-BMR, Mel1617-

BMR) reverses resistance to dabrafenib+trametinib (D/T;
BRAFi/MEKi) by inhibiting viability, colony formation, and
inducing PARP and caspase-3 cleavage in the presence of D/T
(Fig. 3a–g and Supplementary Fig. 3a–c). Moreover, reexpression of ABL1/2 rescues ABL1/2 shRNA-mediated inhibition of survival (Supplementary Fig. 3d). To mimic clinically
relevant mechanisms of resistance, we also developed a cell line
from melanoma cells that developed BRAFi/MEKi resistance,
in vivo (Fig. 3h). Importantly, nilotinib also reverses D/T
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Fig. 3 Blocking ABL1/2 activity reverses resistance to BRAF + MEK inhibitors. a, b CellTiter Glo viability assays using parental and BRAF/MEK-inhibitor
resistant M14 cells treated with nilotinib (nilo; 2.5 μM) in the absence/presence of BRAFi/MEKi (dabrafenib/trametinib; D/T) for 72 h. Results are mean ±
SEM for three independent experiments performed in triplicate. Actual p values left→right: a 0.0015, <0.0001 using two-sided, two-sample t-tests; b 50/
10: 0.031, 0.008, 0.0018; 100/20: 0.0022, 0.0085, 0.00031; 150/25: 0.00037, 0.00018, <0.0001 using two-sample t-tests (two sided). c–e Colony
assays. Cells were treated with vehicle, D/T (100 nM/20 nM) in the absence or presence of nilotinib (2.5 μM), GNF-5 (GNF; 10 μM), or ponatinib (pona;
100 nM) for 7 days, washed, and incubated in the absence of drugs for an additional 6 days (c, e) or treated for 13 days (d). f Cells were treated with
nilotinib (M14-BMR-5 μM; Mel1617-BMR-4 μM) in the absence or presence of D/T (150 nM/25 nM) for 96 h, and detached and attached cells lysed and
subjected to western blotting. Representative blots from n = 2 independent experiments are shown. V = vehicle. g M14-BMR cells expressing scrambled
(shScr) or IPTG-inducible shRNA targeting ABL1 and ABL2 (shABL1/2) were treated with IPTG (1 mM) for 5 days prior to plating, treated with vehicle or D/
T (150 nM/25 nM) for 72 h, and cell viability assessed with CellTiter Glo. Results are mean ± SEM for two vector and two shRNA clones and three
independent experiments for each, expressed as a percentage of vehicle (DMSO). ***p = 7.5e−5 using a two-sample t-test (two sided). Veh = vehicle.
Knockdown efﬁciency (western blots) is shown on the right. h M14 BRAFi/MEKi in vivo-resistant cells were obtained by treating mice containing M14
xenografts (200 mm3) with vehicle or D/T and establishing a cell line from resistant tumor tissue on day 49. Graph is mean ± SEM, n = 5 mice/group. i, j
The established line from h was incubated with nilotinib (2.5 μM if doses are not indicated) in the absence/presence of D/T (100 nM/20 nM, if not
indicated), and viability assessed with CellTiter Glo assay (mean ± SEM for n = 3 independent experiments performed in triplicate, i); and colony formation
assessed as above (growth/treatment for 17days; j) *p < 0.05, **p ≤ 0.01. ***p < 0.001 using two-sided, one-sample t-tests. Actual p values (left→right):
0.0023, 0.00097, 0.0003, 0.0057, 0.00026, 0.00019, 0.00012, 0.00019, and <0.0001. For all experiments, BRAFi/MEKi-resistant lines were maintained
in D/T (100 nM/20 nM) but were cultured for 2 days without D/T prior to plating for experiments.

resistance in this model (Fig. 3i, j), indicating our data have
high clinical relevance.
ABL1/2 drive ERK pathway reactivation during BRAFi resistance. To uncover the mechanism by which ABL inhibitors
reverse resistance to BRAFi, we assessed activation of ERKdependent signaling pathways since ERK reactivation is a common resistance mechanism. ERK activation results in phosphorylation (pFRA1) and induction of the transcription factors,
FRA1/FOSL1 and MYC, which are critical for melanoma development, progression, and resistance27,28. In M14 and Mel1617
BRAFi-resistant cells (-BR), treatment with nilotinib or GNF-5
(highly selective but less potent allosteric inhibitor)12,29 alone has
little effect or modestly reduces expression/phosphorylation of
signaling proteins in resistant cells (Fig. 4a, b and Supplementary
Fig. 4a). Phosphorylation of the ABL1/2 substrate, CRKL, a wellaccepted read-out of ABL1/2 activities13,24, demonstrates the
efﬁciency of nilotinib/GNF-5 inhibition (Fig. 4a–c and Supplementary Fig. 4a). PLX (BRAFi) treatment efﬁciently inhibits ERK
signaling (pERK, pFRA1, MYC) in parental/sensitive lines,
whereas it is inefﬁcient at inhibiting these proteins in resistant
cells (Fig. 4a, b). Signiﬁcantly, addition of nilotinib or GNF-5 to
PLX blocks reactivation of ERK signaling in resistant cells and
also reduces pMEK (S217/S221; activating residues; Fig. 4a, b and
Supplementary Fig. 4a). Moreover, gain-of-function experiments
demonstrate that ABL1/2 activation is not only necessary but also
sufﬁcient to induce pERK/pFRA/MYC (Supplementary Fig. 4b).
Interestingly, in 451-Lu-BR cells, nilotinib, which is highly
effective on its own at reducing cell viability (Fig. 2e, f), also is
highly effective on its own at inhibiting MYC expression and
phosphorylation of MEK1/2, ERK1/2, and FRA1 (Fig. 4c). Thus,
nilotinib alone (451-Lu-BR) or nilotinib in combination with
BRAFi (M14-BR, Mel1617-BR) prevents reactivation of MEK/
ERK signaling during resistance.
To gain additional insight into the mechanism by which
targeting ABL1/2 reverses BRAFi resistance, we performed nextgeneration whole-exome sequencing (WES), identifying new
acquired mutations that are present in resistant lines but not in
parental cells. Mel1617-BR cells have a mutation in MAP2K2
(MEK2; Q60P) (Table 1 and Supplementary Data File 1), which
also was previously identiﬁed in MEKi-resistant Mel1617 and
451-Lu cells30. Mel1617-BR cells also have a catalytic domain
PTEN mutation (G143D); however, the allele frequency is low
indicating it is only present in a small subpopulation. M14-BR
cells harbor an activating mutation in NRAS (Q61R), a known
6

resistance mechanism in patients (Table 1 and Supplementary
Data File 1)31,32, indicating the line is clinically relevant. Contrary
to a previous report33, our WES analysis did not uncover a
MAP2K1 (MEK1; K57N) mutation in 451-Lu-BR cells, and this
result was conﬁrmed using Sanger sequencing (Supplementary
Data File 2 and Supplementary Fig. 4c). We obtained 451-Lu-BR
soon after it was established (2011)17, and short tandem repeat
(STR) analysis in 2018 conﬁrmed its identity. Interestingly,
MAP2K1-K57N was identiﬁed by WES at a very low allele
frequency (1 out of 240 reads), and thus may represent a small
subpopulation of the original line. Unlike M14-BR and Mel1617BR, 451-Lu-BR did not have an obvious ERK pathway mutation.
However, we did identify a mutation in the D-3 domain of
MAP2K7 (MKK7; P68A), a MAP2K (like MEK1/2) that binds
JNK via D-domains, and cooperates with MAP2K4 (MKK4) to
activate JNK34. There is accumulating evidence for crosstalk
(negative and positive) between JNK and ERK pathways; thus,
this mutation could potentially induce ERK reactivation (Table 1
and Supplementary Data File 2)34,35. In summary, BRAFiresistant lines acquire mutations that reactivate ERK signaling
via different mechanisms; however, targeting ABL1/2 reverses
resistance (or is effective on its own) in all lines, indicating that
ABL1/2 are key signaling nodes.
Targeting ABL1/2 prevents ERK or AKT reactivation during
BRAFi/MEKi resistance. Next, we evaluated the mechanism of
ABL1/2-driven resistance to BRAFi/MEKi. In M14-BMR cells,
ERK1/2 is reactivated in the presence of BRAFi/MEKi (dabrafenib/trametinib; D/T), leading to induction of pFRA1/FRA1 and
MYC (Fig. 5a). Paradoxically, D/T treatment induces upregulation of pMEK1/2 (with concurrent downregulation of total MEK)
despite the presence of trametinib (MEKi). This phenomenon has
been postulated to be due to phosphorylation of MEK1/2 (S217/
S221; reﬂects activity) by upstream kinases, which reduces the
afﬁnity of trametinib to the allosteric regulatory site36. Nilotinib
and ponatinib as well as ABL1/2 shRNA resensitize M14-BMR
cells to D/T, reducing pMEK1/2, pERK1/2, pFRA1/FRA1, and
MYC expression (Fig. 5a, b and Supplementary Fig. 5a). Thus,
ABL1/2 inhibition prevents MEK phosphorylation by upstream
kinases.
To gain insight into the mechanism by which targeting ABL1/2
reverses ERK-driven BRAFi/MEKi resistance, we performed nextgeneration WES. We were unable to discern an ERK pathway
mutation in M14-BMR cells that could explain reactivation of
MEK/ERK signaling (Supplementary Data File 1). However, we
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Fig. 4 Nilotinib blocks reactivation of ERK signaling in BRAFi-resistant cells. BRAFi (-BR; R) or parental (P) cells were treated with vehicle, nilotinib (nilo;
2.5 μM), PLX4720 (M14 and 451-Lu 1 μM; Mel1617 2.5 μM) or the combination for 24 h, and the resulting lysates probed with the indicated antibodies.
Quantitation of key signaling molecules for n = 3–5 independent experiments is shown below blots; green arrows indicate lanes quantiﬁed. Mean ± SEM is
shown. M14-BR: pMEK n = 5, pERK n = 4, pFRA1 n = 5, MYC n = 4. Mel1617-BR: pMEK n = 5, pERK n = 3, pFRA1 n = 3, MYC n = 3. 451-Lu-BR: pMEK n = 3,
pERK n = 6, pFRA1 n = 4, MYC n = 5. For M14 and Mel1617 cell lines, data are a comparison between PLX + nilotinib vs. PLX lanes, whereas for 451-Lu cell
lines, nilotinib alone is compared to vehicle (DMSO). *p < 0.05, **p ≤ 0.01, ***p < 0.001 using one-sample t-tests (two-sided). Actual p values (left→right):
a 0.0069, 0.002, <0.0001, and 0.0072. b 0.026, 0.0097, 0.029, and 0.011. c 0.046, <0.0001, 0.00011, and 0.0001. pCRKL (substrate of ABL1/2) is an
indirect read-out of ABL1/2 activity and indicates the efﬁciency of nilotinib-mediated inhibition. For all experiments, BRAFi-resistant lines were maintained
in PLX (1 μM), but were cultured for 2 days without PLX prior to plating for experiments.

MAPK pathway acquired mutations in resistant lines that are not present in parental lines. See
Supplementary Data Files 1 and 2 for complete gene lists.

In Mel1617-BMR cells, modest reactivation of MEK1/2 in the
presence of D/T does not result in induction/activation of ERK1/
2, FRA1, or MYC, and pMEK1/2 levels are unchanged by
combining nilotinib/GNF-5 and D/T (Fig. 5c and Supplementary
Fig. 5b). Thus, ABL1/2 activate an ERK-independent resistance
pathway in Mel1617-BMR. Importantly, AKT phosphorylation,
which is induced by D/T, is reduced by addition of nilotinib or
GNF-5 (Fig. 5c and Supplementary Fig. 5b), indicating that
nilotinib/GNF also reverse BRAFi/MEKi resistance driven by an
ERK-independent mechanism.

did identify a MAP4K1 (MEKKK1; HPK) mutation (P422Q),
which was previously identiﬁed in a patient with cutaneous
melanoma (cBioportal website; Table 1). Although MAP4K1
primarily activates JNK, there is evidence for crosstalk between
JNK and ERK pathways34,35, indicating that this may be a
mechanism by which ERK signaling is reactivated.

ABL1/2 induce resistance via ERK/MYC reactivation. The ERK
pathway is reactivated during resistance in the majority of lines.
To prove that blockade of ERK reactivation is the mechanism by
which nilotinib reverses resistance, we engineered M14-BMR cells
to express a mutant, gain-of-function (GOF) form of ERK2
(D231N/R67S)37. Signiﬁcantly, expression of ERK2-GOF efﬁciently reverses nilotinib’s anti-survival effects in the presence of
D/T, indicating that nilotinib reverses resistance by blocking ERK

Table 1 Next-generation whole-exome sequencing.
Resistant cell lines

MAPK pathway mutations

M14-BR
Mel1617-BR
451-Lu-BR
M14-BMR

NRAS-Q61R
MAP2K1-Q60P
MAP2K7-P68A
MAP4K1-P422Q
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Fig. 5 Nilotinib prevents reactivation of ERK-dependent (or ERK-independent) signaling during BRAFi/MEKi resistance. a, c Parental or BRAFi/MEKiresistant cells (-BMR) were treated with vehicle, nilotinib (nilo; 2.5 μM), dabrafenib/trametinib (D/T; BRAFi/MEKi; 50/10 nM) or the combination for 24 h,
and the resulting lysates probed with the indicated antibodies. Quantitation of key signaling molecules for n = 3 independent experiments (except pERK, n
= 4) is shown below; green arrows indicate lanes quantitated. Mean ± SEM *p < 0.05, **p ≤ 0.01, ***p < 0.001 using two-sided, one-sample t-tests. Actual p
values (left→right): a 0.045, 0.0099, 0.0033, and 0.004. c **p = 0.0045. b M14-BMR cells expressing either vector (shScr) or IPTG-inducible shRNA
targeting ABL1 and ABL2 (shABL1/2; two independent clones are shown) were treated with IPTG (1 mM) for 10 days prior to plating to induce expression,
treated with DMSO (vehicle) or D/T (100 nM/20 nM) for 24 h, and lysates blotted with the indicated antibodies. n = 4 biological replicates (using two
vector and two shRNA clones). **p ≤ 0.01, ***p < 0.001 using two-sided, one-sample t-tests. Actual p values (left→right): <0.0001, 0.011, 0.0056, and
0.000191. pCRKL (substrate of ABL1/2) is an indirect read-out of ABL1/2 activity and indicates the efﬁciency of nilotinib-mediated inhibition. For all
experiments, BRAFi/MEKi-resistant lines were maintained in dabrafenib (100 nM) and trametinib (20 nM), but were cultured for 2 days without BRAFi/
MEKi prior to plating for experiments.

reactivation (Fig. 6a). Since MEK/ERK reactivation during resistance induces MYC (a convergent point in multiple resistance
pathways)28, which is efﬁciently blocked by targeting ABL1/2,
and ABL1 mRNA is upregulated during resistance in primary
melanomas, we examined the clinical signiﬁcance of our ﬁndings
by testing whether ABL1 and MYC expression are linked in
patient samples. Importantly, ABL1 and MYC mRNAs are correlated in melanomas from patients prior to treatment (Fig. 6b,
left) and in the TCGA dataset (Supplementary Fig. 5c), and an
even more signiﬁcant correlation was observed in paired samples
from the same patients following relapse on BRAFi or BRAFi/
MEKi (Fig. 6b, right). Thus, the resistance pathway we identiﬁed
in cell lines also occurs in human patients.
ABL1/2 activate MAP3Ks. D/T treatment induces MEK1/2
(S217/S221) phosphorylation/activation, and silencing or inhibiting ABL1/2 reduces pMEK1/2 in the presence of PLX or D/T
(Figs. 4a, b and 5a, b). Thus, ABL1/2 induce pMEK1/2 which
8

activates ERK1/2 and drives resistance. In BRAFi-resistant cells,
RTKs can activate alternative MAP3Ks (CRAF, MAP3K8), which
activate MEK1/2 thereby circumventing the effects of
BRAFi6,17,36. CRAF directly phosphorylates/activates MEK,
whereas MAP3K8 mRNA/protein upregulation activates
MAP3K8 which directly activates MEK and ERK1/23,6,38.
MAP3K1, another MAP3K, primarily activates MAP2K4/
MAP2K7 (MKK4/MKK7), MAP2Ks that activate JNK; however,
it can phosphorylate MEK1/2 under some circumstances, and
also can activate MEK/ERK indirectly via JNK feedback activation
of ERBB RTKs35,39. To determine whether ABL1/2 regulate
MAP3Ks, we examined whether MAP3Ks were activated/upregulated in resistant cells, and whether altering ABL1/2 activities
prevents their upregulation. In BRAFi-resistant cells, CRAF
(S338; PAK1 site) and MAP3K1 (T1402; activating residue in the
catalytic domain) phosphorylation are induced and MAP3K8
expression is modestly increased, particularly in the presence of
PLX (Supplementary Fig. 6a–d). Interestingly, the predominant
phosphorylated (activated) form of MAP3K1 in melanoma cells is
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140 kDa, which is a known alternatively spliced form (NCBI
website). Addition of nilotinib to PLX reduces pCRAF and
pMAP3K1 in Mel1617-BR cells, whereas nilotinib alone reduces
pMAP3K1 in 451-Lu-BR (Supplementary Fig. 6a–c). M14-BR
cells harbor mutant NRAS, which directly binds/activates
MAP3Ks40. Indeed, pCRAF and pMAP3K1 both are elevated in
M14-BR cells; however, PLX + nilotinib treatment speciﬁcally
reduces pMAP3K1 (Supplementary Fig. 6c, d). Consistent with
nilotinib studies and with the notion that ABL1/2 regulates
MAP3K1 in BRAFi-resistant cells, expression of constitutively
active ABL1/2 in BRAFi-sensitive cells increases MAP3K1 phosphorylation (Supplementary Fig. 6e).

42 kDa

In M14-BMR cells that have acquired BRAFi/MEKi resistance,
MEK phosphorylation is induced in the presence of trametinib
(MEKi), and this resistance mechanism has been postulated to be
due to MEK phosphorylation by upstream kinases which causes
reduced afﬁnity of trametinib to the allosteric site36. MEK1
remains inhibited as reactivated ERK1/2 feeds back and
phosphorylates/inhibits MEK1 (T292); however, this residue is
not conserved in MEK2, and thus, MEK2 remains activated and
drives resistance36. We found that M14-BMR cells harbor a
mutation in MAP4K1, an upstream activator of MAP3K1
(Supplementary Data File 1)39. Consistent with this mutation
being an activating event, MAP3K1 is upregulated
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Fig. 6 ABL1/2 drive ERK reactivation during resistance by promoting MAP3K activation. a M14-BMR cells were engineered to express vector or HAtagged constitutively active ERK2 (GOF)37. ERK2-GOF expression is shown on the upper right. Vector or ERK2-GOF-expressing cells were plated, treated
with D/T (50 nM/10 nM) in the absence or presence of nilotinib (nilo; 2.5 μM) for 7 days, wells washed, cells incubated in media lacking drugs for an
additional 9 days, and stained with crystal violet. Quantitation of mean ± SEM for n = 4 independent experiments is shown on the right. ***p = 0.00084,
two-sample t-test (two-sided). b Primary human paired melanoma datasets (RNAseq-77940, 50535, 65185, EGAS00001000992; microarray-50509)
were analyzed for ABL1 and MYC mRNA levels pre-/post-BRAFi, MEKi or BRAFi/MEKi treatment. Spearman’s correlation coefﬁcients were used to quantify
correlations. Correlation (r), 95% conﬁdence limits (in parentheses), and p values are shown. c M14-BMR or parental M14 cells were treated with the
indicated drugs as in Fig. 5 for 24 h, and lysates blotted with antibodies. A representative experiment from n = 3 independent experiments is shown. Veh =
vehicle. d M14-BMR cells expressing either vector (vec) or IPTG-inducible shRNA targeting ABL1/2 were treated with IPTG (1 mM) for 5 days prior to
plating, treated with DMSO (vehicle) or D/T (100 nM/20 nM) for 24 h, and lysates blotted with the indicated antibodies. A representative experiment
from n = 4 independent experiments is shown. e M14-BMR cells were transfected with MAP3K1, MAP4K1, or scrambled siRNA, cells replated and treated
with D/T (50/10 nM) −/+ nilotinib (2.5 μM) for 24 h, and lysates blotted with antibody (left). A representative experiment from n = 3 independent
experiments is shown. (right) 293T cells were transfected with vector or MAP3K1 (exogenous form runs at 200 kDa), and lysates blotted after 48 h. A
representative experiment from n = 2 independent experiments is shown. Vec = empty vector. f, g ABL1 (f) or MAP3K1 (g) immunoprecipitates (IP) from
M14-BMR-treated cells, were blotted with the indicated antibodies. Representative experiments from n = 4 (f) and n = 3 (g) independent experiments are
shown. Input is whole-cell lysate. Rabbit (f) or mouse (g) IgG served as a negative isotype controls. D/T = 100/20 nM; nilotinib = 2.5 μM; BV02 = 5 μM.

(phosphorylated) in M14-BMR cells, particularly in the presence
of D/T (Fig. 6c). Silencing ABL1/2 inhibits MAP3K1 activity
(pMAK3K1-T1402) in the presence of D/T, and nilotinib/GNF-5
cooperate with D/T to reduce pMAP3K1 (Fig. 6c, d and
Supplementary Fig. 6c, f, g). Although silencing ABL1/2 reduces
pCRAF, nilotinib paradoxically increases pCRAF in the presence
of D/T, similar to our ﬁndings in M14-BR, but this does not result
in increased pMEK/pERK or downstream signaling (Figs. 4a, 5a
and 6c, d).
MAP3K1 reactivates MEK/ERK during BRAFi/MEKi resistance. ABL1/2 inhibition prevents MAP3K1 activation in all cell
lines examined regardless of the mechanism of ERK reactivation,
indicating that ABL kinases likely regulate MAP3K1. To identify
the mechanism of regulation, we focused on the M14-BMR cell
line, since these cells represent a clinically relevant model due to
their resistance to both BRAFi and MEKi, a current treatment
regimen. In breast cancer cells, MAP3K1 activates MEK1/2
indirectly by stimulating an MAP2K4/MAP2K7→JNK pathway,
which results in JNK-mediated positive feedback activation of
ERBB RTKs that activate MEK1/235. However, in M14-BMR
cells, silencing or inhibiting ABL1/2 (in the presence of D/T)
inhibits MEK activity but does not reduce pJNK1/2; thus, ABL1/2
do not activate MEK via this mechanism (Fig. 6c, d). In other cell
contexts, MAP3K1 phosphorylation of MEK1/2 does not activate
ERK in cells41. However, we found that silencing MAP3K1 or
MAP4K1 prevents MEK and ERK reactivation as well as downstream signaling (MYC) during resistance (+D/T) while having
no effect on pJNK (Fig. 6e, left). Exogenous expression of
MAP3K1 in a heterologous system (293T cells) activates MEK/
ERK and JNK but has little effect on MYC (Fig. 6e, right). In
contrast, in M14-BMR cells, exogenous MAP3K1 expression
reduces nilotinib-mediated inhibition of pMEK and MYC, but
has little effect on pJNK (Supplementary Fig. 6h). Thus, taken
together our data demonstrate that ABL1/2 drive resistance by
activating MAP3K1→MEK/ERK/MYC signaling, and although
MAP3K1 has the potential to activate JNK or MEK, it preferentially activates MEK during BRAFi/MEKi resistance.
ABL1-mediated coupling of MAP4K1/MAP3K1 to MEK/ERK
requires interaction with 14-3-3 proteins. Next, we investigated
the mechanism by which ABL kinases impact MAP3K1 activity.
Endogenous ABL1 coimmunoprecipitates (coIPs) with MAP4K1,
pMAP3K1, CRAF, MEK, and ERK in M14-BMR cells exposed to
D/T (Fig. 6f, second lane). We are not able to observe coIP of
total MAP3K1 as all the antibodies we have tested are weak and
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total MAP3K1 levels are low in resistant cells (Fig. 6c). The ABL2
antibody is inefﬁcient at immunoprecipitating ABL2; however, we
were able to observe endogenous coIP of ABL2 with MAP4K1,
pMAP3K1, MEK, and CRAF (Supplementary Fig. 6i). Although
nilotinib treatment (+D/T) increases the ability of the ABL1
antibody to IP ABL1, the binding of MAP4K1, MAP3K1, MEK,
and ERK (but not CRAF) to ABL1 is efﬁciently reduced (Fig. 6f,
fourth lane). Thus, ABL1/2, MAP4K1/pMAP3K1, and MEK/ERK
are all in a complex, and ABL1/2 activity is required for the
interaction.
ABL1 binding to 14-3-3 proteins sequesters ABL1 in the
cytoplasm where it has a transforming function20,21, and
MAP3K1 also binds 14-3-3, although the consequence of this
binding is unknown42. Thus, we tested whether 14-3-3 proteins
mediate binding between ABL1, MAP4K1/MAP3K1, and MEK/
ERK. Importantly, treatment with the 14-3-3 interaction
inhibitor, BV02, prevents binding of MAP4K1, pMAP3K1,
MEK1, and ERK to ABL1 (Fig. 6f, ﬁrst lane). Thus, interaction
with 14-3-3 proteins is critical for formation of the ABL1containing complex. Indeed, ABL1, MAP4K1, pMAP3K1, MEK,
ERK, and CRAF all coIP with 14-3-3 proteins; however, BV02
treatment only prevents ABL1, pMAP3K1, and to a lesser extent,
MAP4K1 from binding 14-3-3 (Supplementary Fig. 6j), indicating
that these proteins mediate the interaction. Similar to nilotinib,
silencing ABL1/2 reduces binding of MAP4K1, MAP3K1, MEK,
and CRAF to 14-3-3, but increases the binding of JNK, indicating
that ABL1/2 are required for formation of MAP4K1/MAP3K1/
MEK but not MAP4K1/MAP3K1/JNK complexes (Supplementary Fig. 6k). Signiﬁcantly, silencing or inhibiting (nilotinib)
ABL1/2 uncouples binding of MAP4K1 to MAP3K1 during ERK
reactivation-driven resistance (Fig. 6g and Supplementary Fig. 6l).
Numerous MAP4Ks have the ability to phosphorylate MAP3K1,
and MAP4Ks can phosphorylate a plethora of MAP3Ks39. Thus,
these data are signiﬁcant as they indicate that ABL1/2 not only
drive signaling of MAP3K1 to MEK/ERK (rather than to JNK/
JUN) but also mediate coupling of the upstream kinase,
MAP4K1, speciﬁcally to MAP3K1.
ABL1/2 phosphorylate MAP3K1 and 14-3-3-ε. Since ABL1/2
activity is required for assembly of the ABL1/MAP4K1/MAP3K1/
MEK/ERK complex and for coupling of MAP4K1 to MAP3K1,
ABL1/2 likely phosphorylate one or more members of the complex. Thus, we examined whether ABL1/2 phosphorylate
MAP3K1 and/or 14-3-3 proteins, since MAP3K1 has been
implicated as a target of ABL1 in other systems43–45, and tyrosine
phosphorylation of 14-3-3 is known to regulate its binding to
other proteins46. Co-expression of MAP3K1 and activated ABL1
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Fig. 7 ABL1/2 phosphorylate MAP3K1 and 14-3-3-ε. a 293T cells were transfected with His-MAP3K1 and/or constitutively active forms of ABL1 or ABL2
(PP), His-MAP3K1 pelleted with nickel agarose, complexes blotted with phospho-tyrosine (pTyr) antibody, and blot stripped and reprobed with control
antibodies. Blots shown are representative of n = 3 independent experiments. b Endogenous MAP3K1 or 14-3-3 (pan) were immunoprecipitated from M14BMR cells, and IPs blotted with the indicated antibodies. Blots shown are representative of n = 2 independent experiments. c Recombinant forms of ABL1 or
ABL2 were incubated with full-length, recombinant MAP3K1 in a “cold” in vitro kinase assay, and reactions blotted with phospho-tyrosine (pTyr) antibody,
stripped and reprobed with antibody to MAP3K1. Blots shown are representative of n = 2 independent experiments. d Recombinant proteins were
incubated in a kinase assay as in c using either His-MAP3K1, GST-14-3-3-ε, or the combination as substrates. The phospho-tyrosine blot (top) was stripped
and reprobed with antibody directed at the MAP3K1 C-terminus (middle) or GST (bottom; to visualize 14-3-3). Blots shown are representative of n = 2
independent experiments. e Scheme showing mechanism by which ABL1/2 drive ERK reactivation and resistance (red arrows).

or ABL2 in a heterologous system results in tyrosine phosphorylation of MAP3K1 (Fig. 7a). Moreover, nilotinib treatment of
M14-BMR cells (in the presence of D/T) reduces MAP3K1 and
14-3-3 tyrosine phosphorylation (Fig. 7b). To conﬁrm that ABL1/
2 phosphorylate MAP3K1 and 14-3-3, and to assess whether the
phosphorylation is direct, we performed kinase assays using
recombinant, puriﬁed proteins. Incubation of MAP3K1 with
ABL1 or ABL2 results in modest tyrosine phosphorylation of fulllength MAP3K1 (Fig. 7c). The supplied recombinant MAP3K1
has some degradation products (see Origene website). Interestingly, ABL1 efﬁciently phosphorylates the 80 kDa breakdown
product, whereas ABL1 and ABL2 phosphorylate a 100 kDa
breakdown product recognized by a C-terminal MAP3K1 antibody (Fig. 7d, left and Supplementary Fig. 7a, left). To test

whether ABL1/2 also phosphorylate 14-3-3, and whether the
presence of 14-3-3 proteins acts as a scaffold to enhance ABL1/2mediated phosphorylation of MAP3K1, we incubated ABL1/2
with GST-14-3-3-ε, a 14-3-3 family member known to bind ABL1
and MAP3K120,21,42. Importantly, ABL1 efﬁciently phosphorylates 14-3-3-ε, and the presence of MAP3K1 enhances the ability
of ABL2 to phosphorylate 14-3-3-ε and vice-versa (Fig. 7d, right
side). Interestingly, ABL1/2 phosphorylate numerous sites on 143-3-ε as increased incubation time (30′ versus 15′) induces a
signiﬁcant band shift which is observed both in phospho-tyrosine
and GST blots (Fig. 7d and Supplementary Fig. 7a, b). Thus,
ABL1/2 phosphorylate MAP3K1 and 14-3-3, and ABL1/2 activity
is required to assemble the ABL1/MAP4K1/MAP3K1/MEK/ERK
signaling complex, which results in MAP4K1 activation of
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MAP3K1, and subsequent MEK/ERK reactivation during D/T
resistance (Fig. 7e).
Nilotinib reverses resistance, in vivo. To determine whether
nilotinib could potentially be utilized as an agent to reverse or
prevent resistance in the clinic, we performed three in vivo studies.
First, Mel1617 parental or BRAFi-resistant xenografts (-BR) were
established (200 mm3) in SCID-beige mice, and mice bearing
parental tumors were treated with vehicle or PLX4720 (to assess
BRAFi-mediated regression of sensitive tumors), whereas mice
bearing the resistant variant were treated with vehicle, nilotinib,
PLX4720 or PLX + nilotinib. Tumor regression was efﬁcient in
parental xenografts treated with PLX (Fig. 8a, open circles),
whereas resistant tumors in mice treated with vehicle, nilotinib or
PLX grew quickly and reached the endpoint in 11 days (Fig. 8a).
In contrast, overall survival was much higher in mice treated with
the PLX + nilotinib combination (Fig. 8b). Interestingly, mice
treated with PLX + nilotinib segregated into two groups
(responders n = 7, non-responders n = 4; Fig. 8a, c). Resistant
tumors completely regressed in responding mice, similar to PLXtreated parental tumors, whereas tumor growth curves of nonresponding mice were no different from controls (Fig. 8a, c). Thus,
PLX + nilotinib, which did not affect mouse weights (Supplementary Fig. 8a), was effective in the majority of mice.
In order to gain mechanistic insight into why some mice
responded well to the combination regimen while others did not,
responding and non-responding tumors (two apiece) were
subjected to WES. There were 84 gene mutations in common
between the four tumors (including MAP2K2-Q60P): 26 genes
unique to both responding tumors and 16 mutations unique to
both non-responding tumors (Supplementary Data Files 3–8). Of
note, both non-responding tumors had a mutation within the
Rho-GEF domain of VAV3, a Rac-GEF and downstream
substrate of BCR-ABL (Supplementary Data Files 3, 6 and 7)47.
Moreover, both responding tumors had the same mutation in
ABI2 (T292S), an ABL1 interacting protein and regulator of ABL1
activity/signaling48. Furthermore, the protein phosphatase N4
(PTPN4), which binds ABL1 and regulates CRK-I (ABL
substrate) phosphorylation49, was mutated in responding and
non-responding tumors; however, the mutation observed in the
responding tumors occurred in a different functional domain
from the mutation observed in the non-responding tumors, and
thus, potentially, could have opposite effects (Supplementary
Data Files 3, 8 and 9). Thus, responding and non-responding
tumors likely originated from two independent cell populations
(even though Mel1617-BR was described as clonal)17, and nonresponding tumors likely did not respond to nilotinib+PLX
treatment due to mutations that resulted in activation of ABL1/2
downstream substrates.
To determine whether nilotinib also reverses resistance to
BRAFi/MEKi, in vivo, parental M14 or BRAFi/MEKi-resistant
(M14-BMR) xenografts were established in nude mice. Mice
harboring parental tumors were treated with vehicle or
dabrafenib+trametinib (D/T), whereas mice harboring M14BMR tumors were treated with vehicle, nilotinib, D/T, or D/T +
nilotinib. Parental tumors grew very quickly and D/T treatment
induced rapid regression (Fig. 8d, orange and red lines). For M14BMR xenografts, D/T only modestly slowed tumor growth, and
nilotinib alone had no effect, whereas the triple-combination (D/
T + nilotinib) induced efﬁcient tumor regression (Fig. 8d). Four
mice from D/T and D/T + nilotinib groups and all vehicle- and
nilotinib-treated mice were euthanized on day 35 due to large
tumor sizes in vehicle/nilotinib groups. Triple-combinationtreated tumors were small and consisted of mostly matrigel with
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occasional small nests of cells (Fig. 8d, e and Supplementary
Fig. 8b), and Kaplan–Meier curves demonstrated elevated overall
survival (Fig. 8f). D/T + nilotinib-treated tumors also had
reduced expression of MYC, consistent with our data in cell
lines and patient samples indicating that ABL kinases drive MYC
expression during resistance (Fig. 8e and Supplementary Fig. 8c,
d). The remainder of the D/T and D/T + nilotinib mice (n = 8/
group) were followed long term. Prolonged tumor regression was
observed in the triple-combination-treated group, whereas all D/
T-treated animals had to be euthanized due to large tumor size
(≅1000–1500 mm3) by day 81 (Fig. 8g and Supplementary
Fig. 8e). Moreover, D/T-treated tumors were highly aggressive
as there was a high rate of lymph node (LN) metastases (75%),
whereas addition of nilotinib to the D/T regimen completely
blocked metastastic progression (Supplementary Table 1).
We continued to follow the triple-combination mice, and
found that 25% (2/8) never exhibited relapse even after following
for 160 days (Supplementary Fig. 8e). The rest of the mice
relapsed between days 95–100 (Supplementary Fig. 8e). CML
patients develop resistance to nilotinib or imatinib by acquiring
kinase domain mutations in ABL1 (e.g. gatekeeper mutation,
T315I), which renders the protein insensitive to the drugs50. To
test whether the resistance we observed was likely due to ABL1 or
ABL2 mutation, we replaced nilotinib with ponatinib, a thirdgeneration ABL inhibitor that inhibits the gatekeeper mutation50.
Unfortunately, due to toxicity of the ponatinib+D/T combination, we were unable to treat mice daily; we often had to withhold
treatment due to anorexia; and the treatment had to be
discontinued after 10 days. However, despite these difﬁculties,
ponatinib induced tumor regression in all treated mice (Supplementary Fig. 8f), indicating that the mechanism of D/T +
nilotinib resistance may involve ABL1 or ABL2 mutation. Thus,
nilotinib reverses resistance to dabrafenib/trametinib, a common
event in the clinic, substantially extending survival. Importantly,
no obvious toxicity was noted for the D/T + nilotinib regimen,
and there was no signiﬁcant change in animal weights despite
treatment for >100 days (Supplementary Fig. 8g).
Nilotinib prevents resistance from developing, in vivo. The
prior data indicate that nilotinib may be an effective add-on
treatment for patients who develop resistance to BRAFi/MEKi.
To test whether nilotinib also prevents resistance from developing
in the ﬁrst place, and thus, whether it could potentially be used in
BRAFi/MEKi-naïve patients, we utilized an in vivo resistance
model. M14 parental cells that are sensitive to BRAFi/MEKi were
established as xenografts in nude mice. Once tumors were wellestablished (mean volume = 200 mm3), mice were treated with
vehicle, nilotinib, D/T, or D/T + nilotinib. Nilotinib alone had no
effect on tumor growth (Fig. 8h), whereas D/T induced rapid
regression followed by relapse and resistance around day 40
(Fig. 8h and Supplementary Fig. 9a). In contrast, D/T + nilotinibtreated animals had prolonged tumor regression with only 8% (1/
12) of animals relapsing (deﬁned as having tumors ≥300 mm3)
within the ﬁrst 70 days of treatment and only 17% (2/12)
relapsing by day 100 as compared to 100% relapse for D/Ttreated mice by day 69 (Fig. 8h, i and Supplementary Fig. 9a).
Moreover, the triple-combination mice had increased
progression-free survival (Supplementary Fig. 9b). Furthermore,
as in the resensitization experiment, the triple combination had
no noticable toxicity, and mice weights were not signiﬁcantly
different between D/T and D/T + nilotinib groups even after
100 days treatment (Supplementary Fig. 9c). Thus, nilotinib not
only resensitizes melanomas to BRAFi/MEKi, but also prevents
resistance from developing in the ﬁrst place.
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Fig. 8 Nilotinib reverses and prevents resistance, in vivo. a–c Mel1617-BR (BR) or parental cells (Mel) were injected s.q. into SCID-beige mice, and when
average tumor size was 200 mm3, Mel1617-BR mice were randomized to vehicle (Veh, n = 12), nilotinib (nilo, n = 12; 33 mg/kg, b.i.d.), PLX4720 (PLX, 25 mg/
kg, n = 12), or combination (n = 11). Parental xenografts were treated with vehicle or PLX (n = 5/group). Mice were euthanized when control tumors ≅1500
mm3 (or were ulcerated). a Individual mouse tumor volumes over time. b Kaplan–Meier survival analysis comparing tumor doubling across groups. Percentage
of mice not reaching the tumor doubling endpoint. Logrank p = 0.00451. PLX + nilo vs. vehicle, p = 0.0202; PLX + nilo vs. nilo, p = 0.0093; PLX + nilo vs. PLX,
p = 0.0202 using pairwise comparisons and Holm’s multiple comparison adjustment. c PLX + nilotinib-treated mice were divided into responding (n = 7) and
non-responding (n = 4) groups, and mean ± SEM tumor volumes plotted. Some SEMs are too small to visualize. One-way ANOVA followed by Sidak’s multiple
comparisons test for responding vs. other groups. veh, p = 0.0104; nilo, p = 0.0004; PLX, p = 0.0027; non-responding, p = 0.0116. d–g M14-BMR (BMR) or
parental M14 (M14) xenografts were established in nude mice. BMR xenografts treated with vehicle, nilotinib (33 mg/kg, b.i.d.), dabrafenib (25 mg/kg/day) +
trametinib (0.15 mg/kg/day) (D/T), or D/T + nilotinib (n = 12/group) when tumors were 200 mm3. Parental xenografts were treated with vehicle or D/T (n =
5/group). d Mean ± SEM tumor volumes. Vehicle/nilotinib-treated mice and four mice from D/T and D/T + nilo groups were euthanized on d35. Linear mixed
model analysis: for all comparisons, p = 3e−04. e H&E and MYC immunohistochemical staining of representative tumors (d) from n = 4 mice/group. f Survival
analysis. Time-to-tumor doubling on d35. Percentage of mice not reaching the tumor doubling endpoint. Logrank p = 1.07e−06. Pairwise comparisons and
Holm’s: p < 6.46e−05 for all groups. g D/T and D/T + nilotinib mice (n = 8/group) were followed long term. Mean ± SEM tumor volumes are shown. Dotted
line indicates loss of euthanized mice (4/group). h, i In vivo prevention study. M14 parental tumors were established in nude mice, and mice treated with the
indicated drugs. Vehicle, n = 5; nilo, n = 6; D/T, n = 11; DT + nilo, n = 12. h Mean ± SEM tumor volumes. Dotted lines indicate loss of mice (high tumor volume
and/or tumor ulceration). i Percentage of mice that developed resistance/relapse (tumors ≥ 300 mm3). Fisher’s exact test, p = 0.0000673 (two sided).
Additional data and statistics related to these experiments are shown in Supplementary Fig. 8.
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Discussion
Despite the development of immunotherapies and BRAFi/MEKi,
the 5-year survival rate for patients with metastatic melanoma
remains low (23%; Cancer.Net). Thus, there is an unmet need for
new drug combinations to extend survival. In this work, using
loss-of-function, gain-of-function and rescue approaches, as well
as cell lines, patient samples, and in vivo approaches, we
demonstrate that ABL1/2 drive resistance to BRAFi and BRAFi/
MEKi by activating MEK/ERK/MYC via alternative MAP3K
pathways. Moreover, we show that ABL1/2 play a critical role in
linking MAP4K1/MAK3K1 to MEK/ERK reactivation during
BRAFi/MEKi resistance. Furthermore, targeting ABL1/2 using an
FDA-approved ABL1/2 inhibitor, nilotinib, resensitizes resistant
cells to BRAFi or BRAFi/MEKi, inhibiting survival and promoting
apoptosis, in vitro, inducing prolonged regression of BRAFi/MEKi
xenografts, in vivo, and preventing resistance from developing in
the ﬁrst place. Thus, these studies indicate that repurposing
nilotinib, an FDA-approved drug used to treat leukemia for more
than a decade, has the potential to prolong melanoma patient
survival in both MAPKi-refractory and treatment-naïve settings.
We provide numerous lines of evidence to demonstrate that
ABL1/2 drive resistance. (1) ABL1/2 are activated in resistant
lines. (2) ABL1 mRNA is elevated in melanomas from patients
that relapse on BRAFi or BRAFi/MEKi therapy. (3) ABL1 cytoplasmic/nuclear ratio and ABL1-T735 phosphorylation (14-3-3
binding site) are increased in resistant cells, consistent with
ﬁndings demonstrating that cytoplasmic retention drives ABL1
oncogenic function9. (4) Constitutively active forms of ABL1/2
drive resistance in treatment-naïve melanoma cells, and induce
MEK/ERK reactivation. (5) Silencing ABL1/2 (and subsequent
rescue with ABL1/2 addback), use of an allosteric inhibitor that
targets only ABL1/2 (GNF-5), and two different ABL1/2 TKIs
(nilotinib, ponatinib) reverse BRAFi/MEKi resistance and prevent
MEK/ERK reactivation. (6) Expression of nilotinib-resistant,
mutant forms of ABL1/2 rescues nilotinib’s anti-survival effects.
Importantly, although the genomic mechanisms of resistance are
different in each line, nilotinib reverses resistance in all lines
queried, indicating that ABL kinases are key signaling nodes
during resistance. Additionally, MYC upregulation is a convergent point for multiple resistance pathways28, and we show
that ABL1/2 drive MYC upregulation during resistance using cell
lines, animal models, and patient samples. Notably, our data also
are consistent with ﬁndings identifying ABL1 in a kinome-wide
screen for overexpressed kinases that can predict resistance to
BRAFi/MEKi51. However, despite these compelling data, due to
the fact that ABL1/2-T315I introduction into M14-BR cells also
increases viability in the absence of nilotinib (a limitation to this
assay; Supplementary Fig. 2g), we cannot completely rule out the
possibility that some of nilotinib’s effects are mediated by nonABL1/2 nilotinib targets.
ERK pathway reactivation is a common mechanism of MAPKi
resistance3,5, and most cell lines we queried acquired resistance in
this manner; however, the mechanisms by which ERK is reactivated are distinct. We identiﬁed activating mutations in
MAP2K2/MEK2 (Mel1617-BR) and NRAS (M14-BR), which are
resistance mechanisms documented in patient samples5, indicating our lines are clinically relevant. The mechanisms of ERK
reactivation in M14-BMR and 451-Lu-BR were more elusive. In
M14-BMR, BRAFi/MEKi activate MEK1/2 indicating that
upstream kinases phosphorylate MEK1/2, which reduces trametinib binding, leading to subsequent MEK2-driven resistance36.
NextGen sequencing revealed that M14-BMR harbor a MAP4K1
(P422Q) mutation that has also been identiﬁed in a melanoma
patient (cBioportal website), and the residue is adjacent to a
critical serine phosphorylation site (S421; PhosphoSite). Phosphorylation of MAP3K1, a downstream substrate of MAP4K1, is
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increased in these cells consistent with the MAP4K1 mutation
being gain-of-function. Interestingly, we show that MAP3K1 is
activated in all resistant lines driven by ERK reactivation (independent of the ERK activation mutation), particularly in the
presence of BRAFi or BRAFi/MEKi, and nilotinib alone (451-LuBR) or nilotinib in combination with MAPK inhibitors (other 3
lines) potently inhibits MAP3K1 phosphorylation/activation. Our
mechanistic data provide insight into how/why this occurs by
demonstrating that MAP4K1/MAP3K1 induce MEK/ERK rather
than JNK/JUN activation during resistance. Moreover, ABL1/2
activity and 14-3-3 proteins are critical for the assembly of
MAP4K1/MAP3K1/MEK/ERK complexes, and ABL1/2 drive
coupling of MAP4K1 to MAP3K1. Our data are consistent with
data obtained in other cell contexts showing that ABL1 interacts
with and/or phosphorylates MAP4K1 and MAP3K143,45,52–54,
and with the identiﬁcation of increased MAP3K phosphopeptides
in imatinib-resistant BCR-ABL1-expressing CML cells (indicates
they are likely substrates)55.
The IGF1 receptor is activated in 451-Lu-BR and Mel1617-BR
cells17; however, nilotinib alone is highly effective at reducing
viability in 451-Lu-BR, whereas nilotinib cooperates with BRAFi
in Mel1617-BR. Interestingly, pCRAF is elevated in Mel1617-BR,
but not in 451-Lu-BR. Moreover, Mel1617-BR has a MAP2K2/
MEK2 mutation (Q60P; analogous to Q56P in MEK1). MEK1Q56P is weakly transforming and must coexist with other lesions
that activate CRAF (e.g. IGF1-R) in order to fully activate ERK
and have complete transforming activity56. In contrast, 451-LuBR harbors a mutation in the JNK-binding domain of MAP2K7
(substrate of MAP3K1; cooperates with MAP2K4 to activate
JNK). Breast cancer cells harboring loss-of-function mutations in
MAP2K4 (and MAP3K1) lack JNK-mediated activation of
ErbB→CRAF→MEK1/2, and thus, are highly sensitive to
MEKi35. Loss-of-function mutations in MAP2K7 would be predicted to act similarly since MAP2K7 and MAP2K4 cooperate to
activate JNK. Indeed, 451-Lu-BR cells are highly sensitive to
trametinib, in contrast to Mel1617-BR cells, which display collateral resistance to trametinib (Supplementary Fig. 10), and 451Lu-BR are highly sensitive to nilotinib, which also reduces
pMEK1/2. Furthermore, pJNK is repressed in 451-Lu-BR cells
(compared to the parental line), which is consistent with 451-LuBR cells harboring a MAP2K7 loss-of-function mutation (Supplementary Fig. 6b). Thus, loss-of-function mutations in
MAP2K7 (and also likely MAP2K4 and MAP3K1) could potentially be biomarkers for resistant tumors that are highly sensitive
to nilotinib alone, and thus may identify patients that could
beneﬁt from monotherapy; future experiments will address this
exciting possibility.
The data shown here have high clinical and translational
relevance. In the in vivo resensitization assay, D/T + nilotinib
signiﬁcantly increased survival, and in the in vivo prevention
study, 83% of mice never developed resistance to the triple
combination even after 100 days of treatment. Nilotinib has been
FDA-approved since 2007; its safety/toxicity proﬁle is known; a
400 mg (b.i.d.) dose, which is used for drug-resistant CML, results
in 1.95 μM plasma concentrations, well within the range of our
in vitro doses; and our in vivo dose (33 mg/kg) is the same or
lower than doses utilized by others in CML models57–59. Moreover, mice treated with the triple combination exhibited no
noticeable toxicity despite use for 100–160 days. Taken together,
these data indicate that the triple combination may be an effective
therapy for treatment-refractory BRAF-driven melanomas.
Indeed, we are currently planning a Phase I trial to test the safety
and efﬁcacy of the triple combination in the second-line setting. If
positive, this may lead to critical prevention studies, where the
combination has the potential to increase survival of melanoma
patients from the outset.
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Methods
Reagents. Cell lines: M14 cells were obtained from NCI (NCI-60 panel) in 2016.
Mel1617, Mel1617-BR, 451-Lu, 451-Lu-BR (c5), and WM164 were obtained from
Meenhard Herlyn (Wistar Institute, Philadelphia, PA) via an MTA in 2011.
Mel1617-BR and 451-Lu-BR were described as clonal lines, established by culturing
cells in increasing doses of the BRAFi, SB590885, followed by isolation of individual clones17. Resistant lines were maintained in SB590885 (1 μM). Short tandem
repeat (STR) analysis was repeated on the four cell lines in 2018 (Wistar Institute,
Philadelphia, PA). Polyclonal M14-BR, M14-BMR, and Mel1617-BMR lines were
generated in our lab from M14 and Mel1617 parental cells by culturing cells in
increasing concentrations of the vemurafenib analog, PLX4720 (M14-BR; up to 1
μM) or dabrafenib+trametinib (M14-BMR; Mel1617-BMR up to 100 nM/20 nM)
until resistant at the indicated dosage (≅6 months), and pooling resistant clones.
M14-BR was maintained in PLX (1 μM), whereas -BMR lines were maintained in
D/T (100 nM/20 nM).
Antibodies: See Supplementary Table 2 for commercial antibodies and their use.
The ABL2 antibody used for coIP and kinase assays was previously described18,19.
DNA constructs and stable expressing cell lines: pBabe-puro-HA-ERK2-GOF
(D231N, R67S; plasmid #53203) deposited by Chris Counter (Duke University,
Durham, NC), GST-14-3-3-ε (#13279) deposited by Michael Yaffe (MIT, Boston,
MA), and His-MAP3K1 (#12181) deposited by Gary Johnson (UNC, Chapel Hill,
NC) were obtained from Addgene (Watertown, MA). M14-BMR cells expressing
HA-ERK2-GOF were obtained by transfecting either the vector or ERK2-GOF into
M14-BMR cells using Lipofectamine 2000 (Invitrogen; manufacturer’s
instructions), selecting clones with puromycin (0.5 μg/ml), picking individual
clones, and screening for expression by blotting with HA antibody. Positive clones
were pooled. Constitutively active ABL1 and ABL2 (PP)26 were removed from their
vectors (pSGT-ABL1-PP, BamH126; PK1-ABL2-PP, EcoR1/XhoI60) blunted and
cloned into the SwaI site of PiggyBac cumate-inducible transposable vector
(Systems Bioscience; Palo Alto, CA). Vector or ABL1/2 constructs were stably
transfected into WM164 cells using Lipofectamine 2000, selected with puromycin
(1.2 μg/ml), and clones were pooled (polyclonal population). FACS analysis
indicated >90% of cells were GFP positive. Expression was observed in the absence
(leaky) and presence of cumate. Low-level expression can be observed via phosphoCRKL blotting, which is an indirect measurement of ABL1/2 activity. M14-BR cells
expressing nilotinib-resistant ABL1/2 mutant (T315I) forms61 were established by
transfecting ABL1/2-T315I, cloned into the Piggybac Transposon vector (see
above), followed by puromycin selection (1.2 μg/ml) and pooling resistant clones.
siRNA and shRNA-expressing cell lines: MAP3K1 (s8669) and MAP4K1
(s22080) silencer select siRNAs (or scrambled control #1) were obtained from
ThermoFisher (Waltham, MA). Cells expressing IPTG-inducible shRNA targeting
ABL1 and ABL2 (PLK01-IPTG-3XLacO vector; custom synthesis-Millipore Sigma,
St. Louis, MO; GGGAAATTGCTACCTATGG) were obtained following lentiviral
infection and selection with puromycin (0.5 μg/ml). Clones were picked, expanded,
and screened for knockdown by western blot. Inducible shRNA-expressing cells
were treated with IPTG (1 mM; Sigma; 6 days) prior to screening. Cells were
treated with IPTG (1 mM) for 5–10 days prior to plating for CellTiter Glo, colonyforming assays, or western blots.
Drugs: GNF-5 and SB590885 were purchased from Selleck (Houston, TX),
whereas ponatinib, nilotinib (for in vitro experiments and for PLX4720 + nilotinib
in vivo experiments), and trametinib were purchased from MedChem Express
(MCE, Monmouth Junction, NJ). Nilotinib (for D/T + nilotinib in vivo
experiments) and dabrafenib were kindly provided by Novartis (Switzerland) under
a Materials Transfer Agreement (MTA). PLX4720 for in vitro and in vivo use was
obtained under an MTA with Plexxikon Inc. (Berkely, CA). SU6656 was purchased
from Calbiochem (VWR; Atlanta, GA). BV02 was from MilliporeSigma.
Puriﬁcation of GST-fusion proteins (GST-CRK, GST-14-3-3-ε). Log-phase BL21
bacteria transformed with the constructs were induced with IPTG (0.1 mM) for 5 h,
pellets were lysed in MT-PBS (150 mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4,
50 mM EDTA, pH 7.3 + inhibitors—see below), Triton X was added (1% ﬁnal),
supernatant was incubated with glutathione sepharose for 30′, beads were washed
3× in MT-PBS followed by elution buffer lacking glutathione (100 mM Tris, pH 8,
120 mM NaCl), and eluted in elution buffer containing 15 mM reduced glutathione. Elutions were pooled, dialyzed against phosphate-buffered saline (SlideA-Lyzer), and quantitated via SDS/PAGE comparing to a known standard (BSA).
In vitro kinase assay. ABL1/2 assay: Subconﬂuent cells were serum-starved for 16
h, and lysed in kinase lysis buffer [50 mM HEPES pH 7.0, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, and fresh protease and
phosphatase inhibitors (leupeptin 10 μg/ml, pepstatin 10 μg/ml, aprotinin 10 μg/ml,
PMSF 1 mM, NaF 25 mM, sodium orthovanadate 1 mM)]. Lysates were precleared
with rabbit IgG (ABL1) or normal rabbit serum (ABL2) and protein-A sepharose.
ABL1 or ABL2 was immunoprecipitated from cellular lysates (30–50 μg ABL1;
60–100 μg ABL2) using agarose-conjugated K12 antibody for ABL1 or an ABL2speciﬁc antibody19 and protein-A sepharose for ABL2. IPs were washed twice in
RIPA buffer, twice in NaCl buffer (10 mM Tris, pH 7.4, 5 mM EDTA, 1% Triton X100, 100 mM NaCl, inhibitors), twice in the previous buffer lacking NaCl, and
twice in kinase buffer (20 mM Tris pH 7.4, 10 mM MgCl2, 1 mM DTT), and
incubated for 40 min at room temperature in kinase buffer containing 1 μM cold
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ATP, 5 μCi [γ-32P]ATP (Perkin Elmer, Greenville, SC) and 1 μg of GST-CRK
substrate. Kinase reactions were run on SDS-PAGE gels (10%), stained with
Coomassie blue (0.25 in 50% methanol/10% glacial acetic acid), destained, dried,
and exposed to ﬁlm. Bands were quantitated with ImageJ64 (online tool; v1.44o).
We previously documented the high speciﬁcity and sensitivity of this assay62.
Recombinant kinase assays: His-tagged, recombinant ABL1 or ABL2
(ThermoFisher, Waltham, MA; 25 ng) were incubated with His-tagged, full-length
MAP3K1 (contains some breakdown; Origene; 100 ng), and/or GST-14-3-3-ε (100
ng) in the above kinase assay buffer containing 1 mM cold ATP, and no “hot” ATP,
and incubated for 30′ (or 15′ where indicated) at 37 °C. Kinase assays were run on
SDS/PAGE gels and blotted with phospho-tyrosine antibody.
Immunoprecipitation-IP/co-immunoprecipitation. 293T cells were transfected
with His-tagged MAP3K1 in the absence/presence of constitutively active ABL1 or
ABL2 (PP), using the calcium phosphate method63, cells were lysed in RIPA buffer,
lysate was precleared with NTA-agarose (Qiagen, Germantown, MD), and Histagged MAP3K1 was pulled down with nickel agarose (Qiagen). After 3 h incubation, precipitates were washed 3× in lysis buffer containing 20 mM imidazole,
resuspended in 2× SDS-sample buffer containing 400 mM imidazole, and run on
SDS-PAGE gels. For coIPs, cells were lysed in TNEN buffer (50 mM Tris, pH 7.5,
50 mM NaCl, 2 mM EDTA, 0.5% NP-40 + inhibitors—see above)16,64, lysate
precleared with mouse or rabbit IgG and protein-A (rabbit) or protein G (mouse)
sepharose (1 h), immunoprecipitated with agarose-conjugated antibodies (3 h),
washed 3× in lysis buffer, and complexes run on SDS-PAGE gels and blotted.
Subcellular fractionation. Cytoplasmic/nuclear lysates were prepared with the
NE-PER kit (ThermoFisher). Equal percentages of cytoplasmic and nuclear fractions were loaded for each cell line, and ABL1 cytoplasmic:nuclear ratios were then
compared between cell lines following quantitation on ImageJ64 (v1.44o).
Viability assays. CellTiter Glo (CTG): Viability was assessed by plating cells in 96well plates, treating the next day with drugs for 72 h, followed by harvest with
CellTiter Glo (Promega, Madison, WI) according to the manufacturer’s instructions. Cells were subconﬂuent at harvest. Assays were performed using three-drug
doses (alone/combination). All cell lines were taken off of drugs for 2 days prior to
plating cells for experiments. MTT assays: Cells were plated in 96-well dishes, and
drug-treated. After 72 h, washed cells were treated with MTT solution (5 mg/ml; 4
h, 37 °C. The supernatant was removed, and formazan crystals were dissolved with
100 μl DMSO. Absorbance at 570 nm was measured with a microplate reader.
Western blotting. Equal amounts of cellular lysate (BCA protein estimation;
BioRad; Hercules, CA) were run on SDS-PAGE gels, transferred to nitrocellulose,
blocked with 5% milk/TBST (0.1%), and incubated with antibodies at the concentrations and stringencies noted in Supplementary Table 2.
In vivo assays. (1) Mel1617 reversal of BRAFi resistance xenograft assay: Mel1617
or Mel1617-BR (2 × 106) cells (in 1× Hank’s Balanced Salt Solution; HBSS; Lonza,
Greenwood, SC) were injected subcutaneously into SCID-beige mice (6 weeks old,
female) together with matrigel (100 μl high concentration, BD Biosciences 1:1 ratio
with HBSS). When tumors reached a mean volume of 200 mm3, parental control
mice were randomly assigned to either vehicle or PLX4720, whereas mice harboring Mel1617-BR tumors were randomly assigned to vehicle (DMSO: PEG400:
Vitamin E TPGS: Poloxamer 407; PBS 1× 5:25:10:1:59), nilotinib (33 mg/kg, b.i.d.;
o.g.), PLX4720 (25 mg/kg, 1× daily, o.g.) or combination treatment groups.
PLX4720 dosage was 50 mg/kg/day initially, as recommended by Plexxikon Inc.,
but due to anorexia, the dose was reduced to 25 mg/kg after 2 days. Mice were
treated until the study endpoint (largest tumors reached 1500 mm3 or were
ulcerated, thus requiring euthanasia).
(2) M14-BMR-reversal of BRAFi/MEKi resistance xenograft assay: Parental M14
cells or BRAFi/MEKi-resistant M14-BMR cells (5 × 106 cells) were injected
subcutaneously into athymic nude mice (6 weeks old, female). When the mean
tumor size was 200 mm3, mice harboring resistant cells were randomized to vehicle
(see above), nilotinib (33 mg/kg, b.i.d.; o.g.), dabrafenib (25 mg/kg, 1×/daily, o.g.;
D) + trametinib (0.15 mg/kg, 1× daily, o.g.; T) or the combination, whereas mice
harboring parental xenografts were treated with vehicle or D/T. Parental-vehicletreated mice were euthanized when the largest tumor approached 1500 mm3. For
mice bearing M14-BMR tumors, all vehicle- and nilotinib-treated mice and four
animals from D/T and D/T+ nilotinib groups were euthanized on day 35 (some
vehicle and nilotinib tumors had reached 1500 mm3), and residual tumor/matrigel
dissected. The remainder of D/T− and D/T+ nilotinib-treated mice (n = 8/group)
were followed long-term, and D/T mice were euthanized when each tumor reached
1500 mm3. When some D/T+ nilotinib animals eventually relapsed (≅day 95),
they were treated with ponatinib (30 mg/kg/d, o.g.). If mice showed signs of toxicity
(weight loss, anorexia), ponatinib was withdrawn until symptoms improved.
(3) In vivo resistance assay: To mock resistance that occurs in patients, parental,
BRAFi/MEKi-sensitive M14 melanoma cells were injected into athymic nude mice,
and when the mean tumor volume reached 200 mm3, mice were randomly assigned
to vehicle, nilotinib, D/T, and D/T + nilotinib groups. Tumors initially regressed on
D/T, but later developed resistance, similar to what is observed in patients. A cell line
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was obtained from a resistant tumor by excising the tumor under sterile conditions,
mincing into 3–4 mm pieces, treating with collagenase B (100U/ml; Roche) and
dispase (1.5U/ml; Roche) in HBSS for 20′ at 37 °C (5 ml volume), centrifuging for 5′
at 800g, resuspending the cells in media containing D/T, and plating in a 100 mm
dish. Mice were euthanized when each tumor reached 1500 mm3. All animal
experiments were performed in the University of Kentucky Biomedical Biological
Sciences Research Building vivarium barrier facility with ambient air temperature of
70 °F, cage temperature of 75–76 °F, 50% humidity, and 14/10 light/dark cycle. All
animal experiments were approved by the Institutional Care and Use Committee
(IACUC) at the University of Kentucky (Protocol #00946M2005), and experiments
were performed in accordance with University and NIH guidelines.
Immunohistochemistry. Tumors from mouse xenograft studies were ﬁxed in
formalin (24 h), followed by incubation in 70% ethanol (at 4 °C) until sectioning.
The Markey Cancer Center Biospecimen and Tissue Procurement Shared Resource
performed immunohistochemistry. Slides containing 4 μm sections were stained
with anti-MYC antibody (Y69, Roche Catalog #790-4628) on a Ventana Discovery
Ultra auto-stainer (antibody is prediluted at an estimated concentration of 24 μg/
ml). Visualization was carried out with Ventana Ultramap Alkaline Phosphatase
reagent (Roche # 760-4314) and Discovery Red Chromogen (Roche #760-228)
according to the manufacturer’s recommendations. Slides were blindly scored by a
pathologist (D. Richards), and photographs were obtained following scanning on
an AperioScan Digital Scope (Leica Biosystems, Cincinnati, OH).
Statistical analysis. General: For in vitro studies, two-sample (comparisons
between-treatment groups) or one-sample t-tests (comparisons against normalized
controls) using the Holm’s method for multiple comparisons adjustment was
performed. For in vivo studies, ANOVA with Sidak correction for multiple comparisons was used to compare tumor volume across treatment groups.
Kaplan–Meier curves and the logrank test with the Holm’s method for multiple
comparisons adjustment were used to compare time-to-tumor doubling across
treatment groups. For all analyses, two-tailed P values are reported.
Analysis of Existing Microarray and mRNA-Seq Clinical Datasets (Pre-/PostERK pathway therapy): Datasets for Fig. 1d/Supplementary Fig. 1f were
downloaded from the GEO database (accession #: 50535, 50509, 77940), and bam
ﬁles for EGAS1000992 were kindly provided by Drs. Lawrence Kwong (MD
Anderson, Houston, TX). A two-sided binomial was utilized to analyze whether
ABL1 mRNA was elevated or downregulated following resistance. In Fig. 6b, three
mRNA-Seq datasets were utilized: GSE50535, GSE77940, and EGAS00001000992.
Since the sample sizes of these datasets were limited, in order to increase sample
size and therefore statistical power, we combined datasets with the R package “sva”,
which removes batch effects using an empirical Bayesian framework65. After
combining the datasets, Spearman’s rank-order correlation analysis was performed
to test the correlations between ABL1 and MYC before and after treatment,
respectively. For Supplementary Fig. 5c, RNASeq data were downloaded from
Genomic Data Commons (GDC) for TCGA Skin Cutaneous Melanoma data
(access date, November 2019) and normalized to Transcripts Per Kilobase Million
(TPM). Spearman’s correlation coefﬁcients were used to quantify the correlation
between ABL1 and MYC mRNAs.
Sequencing. Whole-exome sequencing: WES was performed by the University of
Kentucky Markey Cancer Center Oncogenomics Shared Resource. DNA was
sheared using the Covaris E220 sonicator. Library preparation and exome capture
was performed using the Agilent SureSelectXT Clinical Research Exome v2. Pairedend sequencing was done on an Illumina HiSeq 2500 in rapid run mode (2 × 100
bp). Sequencing reads were trimmed and ﬁltered using Trimmomatic (V0.39)66,
then aligned to human reference genome b37/hg19 using BWA (V. 0.7.17)67.
PCR duplicates were removed using Picard (v2.20.2; http://broadinstitute.github.io/
picard/). The Genome Analysis Toolkit (GATK v4.1.2.0)68 was used for base
quality score recalibration. For comparisons between resistant lines and their
parental counterparts, somatic mutations present in the resistant line but not
in the parental line were detected using Mutect269 (part of the GATK toolkit)
tumor/normal mode with the parental line as the reference. Mutations passing
the contamination ﬁlter and orientation bias ﬁlter were annotated (Oncotator,
v1.9.9.0)70.
Sanger sequencing of MAP2K1 in genomic DNA isolated from 451-Lu-BR cells
was performed by ACGT, Inc. using the primers described in Supplementary
Table 3, and visualized with 4 Peaks software (free online tool).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Kwong; MD Anderson, TX; European Genome-phenome Archive) are below. https://
portal.gdc.cancer.gov/projects/TCGA-SKCM; https://www.ebi.ac.uk/ega/datasets.
All the other data supporting the ﬁndings of this study are available within the article
and its supplementary information ﬁles and from the corresponding author upon
reasonable request. Source data are provided with this paper.
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